Renata PLC announcements
340 Dhaka Stock Exchange announcements for Renata PLC (RENATA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (38).
- Notice of EGM of the company
Refer to their earlier news disseminated by DSE on 24.11.2024, the company has further informed that the EGM will be held on January 12, 2025 at 12:00 noon through Digital Platform Link-https://meetbd.live/renataegm2025 to transact the following business: 1. To pass Special Resolution for issuance of BDT 3,250,000,000 (Taka Three hundred and Twenty-Five Crore) through issuance of Non-Cumulative, Non-Participative, Redeemable or Fully Convertible Preference Shares-At the Issuer's discretion. (cont.) (cont. news of RENATA): 2. To consider and adopt the increase of Authorized Capital of the company. 3. To print new Memorandum and Articles of Association of the company. To view the details of notice of the EGM, please visit the following link- https://www.dsebd.org/Annexure/2024/Renata-EGM-2024.pdf (end)
- Renata PLC launches Rosuvastatin in the U.S. Market
The company has informed that it has successfully dispatched its first shipment of Rosuvastatin to the U.S. market, manufactured at Renata's US FDA-approved facility in Bangladesh. The company has also informed that Renata's product-better known by its brand name Rolip, has been one of the leading and most trusted brands in the Bangladesh market for Rosuvastatin. (cont.) (Continuation news of RENATA): Rolip will now be available in the U.S. market as a bioequivalent and interchangeable formulation to the innovator product. Rolip is available in dosage strengths of 5 mg, 10 mg, 20 mg, and 40 mg tablets. (end)
- Resumption after Record Date
Trading of the shares of the company will resume on 15.12.2024.
- Suspension for Record Date
Trading the shares of the company will remain suspended on record date i.e., 12.12.2024 for EGM.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 10.12.2024 to 11.12.2024 and trading of the shares will remain suspended on record date i.e., 12.12.2024 for EGM.
- Issuance of Non-Cumulative, Fully Convertible Preference Shares
The company has informed that the Board of Directors of the Company has decided to issue Non-Cumulative, Non-Participative, Redeemable or Fully Convertible Preference Shares - At the Issuer's Discretion amounting up to BDT 3,250 million to refinance the existing loans subject to approval from the shareholders of the Company in Extra-Ordinary General Meeting to be held on January 12, 2025 and Bangladesh Securities and Exchange Commission. The 'Record Date' for EGM on Thursday, December 12, 2024.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 5.19 for July-September 2024 as against Tk. 8.89 for July-September 2023; Consolidated NOCFPS was Tk. (0.04) for July-September 2024 as against Tk. 8.80 for July-September 2023. Consolidated NAV per share was Tk. 300.95 as on September 30, 2024 and Tk. 295.56 as on June 30, 2024.
- Q1 Financials (Additional Information)
The company also informed that EPS has decreased due to significant increase in cost of sales & operating expenses, devaluation of BDT against foreign currencies & increase of interest rate have contributed to dumpen profitability & eventually decreased EPS significantly. NOCFPS has decreased significantly in this quarter compared to the same period of prior year impacted by significant degrowth in profit for the period, investment in capital expenditures and significant cash tied up in working capital.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- Resumption after Record date
Trading of the shares of the company will resume on 22.10.2024.
- Launching of the first generic version of Cabergoline 0.5mg in Australia
The company has informed that it has successfully dispatched its first shipment of the generic version of Cabergoline 0.5mg in Australia. The medicine is an effective treatment for Hyperprolactinemia and Parkinson's disease. The distribution and commercialization of Cabergoline, marketed under the brand name Dostamine, will be facilitated in Australia through Renata's partner, Nova Pharmaceuticals Australasia Pty Ltd.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 21.10.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.10.2024 to 20.10.2024 and trading of the shares of the company will remain suspended on record date i.e., 21.10.2024.
- Credit Rating Result
Alpha Credit Rating Limited (AlphaRating) has assigned the Surveillance rating of the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook based on audited financial statements of the Company as on June 30, 2024 and relevant qualitative information till October 07, 2024.
- The company has informed that it has successfully dispatched its first shipment of Sertraline 100mg and Propylthiouracil
The company has informed that it has successfully dispatched its first shipment of Sertraline 100mg and Propylthiouracil 50mg tablets to the UK market. These high-quality products are manufactured at their UK MHRA-approved facility in Rajendrapur, Bangladesh. Under Renata UK\'s branding and in partnership with a local commercialization team, these medications will soon be available to UK consumers. (cont.)
- Launching two new products in the UK market
(Continuation news of RENATA): In Bangladesh, these same products are known under their local brand names, Seronex (Sertraline) and PTU (Propylthiouracil), solidifying Renata's commitment to delivering excellence both locally and globally. (end)
The first part of this announcement is missing from the archive. - The Company has requested the shareholders to update their respective BO Account with 12 digits e-Tin numbers through re
The Company has requested the shareholders to update their respective BO Account with 12 digits e-Tin numbers through respective DPs (broker houses) and shareholders bearing Folio Numbers are requested to submit their 12 digits e-TIN certificate to the Share Department of the Company by October 21, 2024. (cont.)
- Dividend Declaration
The Board of Directors has recommended 92% Cash Dividend for the year ended June 30, 2024. Date of AGM: 05.12.2024, Time: 11:30 AM, Venue: Digital Platform. Record Date: 21.10.2024. The Company has also reported Consolidated EPS of Tk. 31.53, Consolidated NAV per share of Tk. 295.56 and Consolidated NOCFPS of Tk. 18.16 for the year ended June 30, 2024 as against Tk. 20.40, Tk. 266.87 and Tk. 18.18 respectively for the year ended June 30, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.09.2024) following its corporate declaration.
- Update of Information
(Cont. news of RENATA): If anyone fails to provide e-TIN, Tax to be deducted @15% instead of 10% (individual) as per amended Income Tax Act, 2023, Section 117. The Company has also requested the shareholders to check and update their BOID's e-mail address, mobile number and Bank Account details alone with Routing Number to get Dividend online through BEFTN system. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on September 28, 2024 at 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- The company has informed that it has achieved successful approval of Cabergoline 0.5 mg tablets under the EU Decentraliz
The company has informed that it has achieved successful approval of Cabergoline 0.5 mg tablets under the EU Decentralized Procedure (DCP). This approval comes with access to several European markets such as Ireland, France, Portugal, Italy, Denmark, Sweden, Netherlands, Norway, and Spain. Cabergoline, a dopamine agonist, is primarily used in the treatment of conditions such as hyperprolactinemia and Parkinson\'s disease. Cabergoline 0.5 mg will be manufactured at Renata\'s state-of-the-art (cont.1)
- (Cont. News of RENATA): UK MHRA approved potent facility, which adheres to stringent quality control measures and is equ
(Cont. News of RENATA): UK MHRA approved potent facility, which adheres to stringent quality control measures and is equipped to meet the demands of the European market. This product will be distributed across Europe through various of strategic partnerships, ensuring widespread patient access. (cont.2)
The first part of this announcement is missing from the archive. - Regarding achieving EU DCP Approval for Cabergoline 0.5 mg Tablets
(Cont. News of RENATA): Furthermore, this product, qualified for global markets, is available in the local market of Bangladesh under the name Cabolin, ensuring that patients have access to the same high-quality treatment options across the board. (end)
The first part of this announcement is missing from the archive. - Board approval to sign an agreement with IFC to avail foreign loan
The company has informed that the Board of Directors of the company has given consent to sign an agreement with International Finance Corporation (IFC) to avail the foreign loan facilities of USD 60,000,000.00 (US Dollar Sixty Million) as Working Capital and its tenure shall be for 6 (six) years.
- Launching of new Dermatological Drug Terbinafine in the UK Market
The company has informed that it has shipped the initial consignment of Terbinafine 250 mg tablets to the UK market, known by its brand name of Terbimax in Bangladesh. The product is being supplied directly from the Company's UK MHRA-approved facility in Rajendrapur, Gazipur and will be commercialized under the livery of Renata (UK) Limited.
- Renata PLC's first drug registered in Australia
The company has informed that it has shipped the initial consignment of Levonorgestrel 1.5 mg, known by its brand name of Novella-1, which is the first registered product of Renata in Australia. The distribution and commercialization of Novella-1, will be done in Australia through Renata's partner Nova Pharmaceuticals Australasia Pty Ltd.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.38 for January-March 2024 as against Tk. 5.06 for January-March 2023; Consolidated EPS was Tk. 22.95 for July 2023-March 2024 as against Tk. 23.34 for July 2022-March 2023. Consolidated NOCFPS was Tk. (1.31) for July 2023-March 2024 as against Tk. 0.49 for July 2022-March 2023. Consolidated NAV per share was Tk. 283.62 as on March 31, 2024 and Tk. 266.87 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Renata PLC's first direct supply to the US market
The company has informed that they shipped 12.8 million tablets of Metoprolol Tartrate to the US Market on April 04, 2024. It is the first time the Company supplied a product directly from its US-FDA approved facility in Rajendrapur, Gazipur. It should be noted that Renata entered the US market in 2022 with Frovatriptan, followed by the launch of Metolazone in 2023. However, those two products were contract-manufactured elsewhere.
- BSEC's consent for issuance of preference shares
Refer to their earlier news disseminated on 22.10.2023 regarding dividend declaration & issuance of preference share and zero coupon bond, the company has further informed that Bangladesh Securities and Exchange Commission has given its consent for issuance of redeemable, cumulative, non-convertible and non-participative preference shares amounting Tk. 3,500.00 million through private offer.
- Buy Confirmation of Managing Director
Mr. Syed S. Kaiser Kabir, Managing Director of the company, has further informed that he has completed his buying of 10,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 19.02.2024.
- Buy Declaration of Managing Director
Mr. Syed S. Kaiser Kabir, Managing Director of the company, has expressed his intention to buy 10,000 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Name Change of the Company
Dhaka Stock Exchange PLC. (DSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Renata PLC' instead of 'Renata Limited' with effect from February 13, 2024. Other things (except name) will remain unchanged.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 7.68 for October-December 2023 as against Tk. 7.42 for October-December 2022; Consolidated EPS was Tk. 16.57 for July-December 2023 as against Tk. 18.28 for July-December 2022. Consolidated NOCFPS was Tk. 2.80 for July-December 2023 as against Tk. (2.50) for July-December 2022. Consolidated NAV per share was Tk. 277.23 as on December 31, 2023 and Tk. 266.87 as on June 30, 2023.
- BSEC's consent for issuance of Secured, Non-Convertible Zero Coupon Bond
Refer to the earlier news of the Company disseminated by DSE on 22.10.2023, the company has further informed that Bangladesh Securities and Exchange Commission (BSEC) vide their letter Ref: BSEC/CFD/CRD/DS-241/19 dated January 22, 2024 has given their consent for issuance of 5 years Secured, Non-Convertible, and Fully-Redeemable Zero Coupon Bond of an amount up to BDT 6,601.50 million through private placement. The fund would be utilized for refinancing existing loans.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 27, 2024 at 12:45 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.